Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.
Why Sun Pharma’s massive Organon buyout is winning over investors where Lupin, Biocon failed
